Business Context and Reporting Period
This Form 8-K Current Report was filed by Amedica Corporation (not Sintx Technologies, Inc.) on January 20, 2017, regarding events occurring on January 19, 2017. The filing details the entry into a material definitive agreement for a public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Securities Issued: 8,900,000 shares of Common Stock and warrants to purchase 4,005,000 shares.
- Offering Price: $0.51 per share of Common Stock; 0.45 Warrants per share.
- Net Proceeds: Approximately $3.7 million expected after underwriting discounts, commissions, and estimated expenses.
- Warrant Terms: Initial exercise price of $0.55 per share; exercisable immediately upon closing; expire five years from the closing date.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to an additional 15% of shares and warrants.
- Closing Date: Expected on or about January 24, 2017.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes
The primary material change is the execution of the Underwriting Agreement with Maxim Group LLC. This transaction represents a significant capital raise intended to increase the company's cash position, subject to customary closing conditions.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the pricing of the Offering. The filing notes that the offering is subject to satisfaction of customary closing conditions. No specific forward-looking guidance regarding future revenue or earnings is provided in this text. The filing incorporates by reference the Underwriting Agreement and Form of Warrant for full details on terms and potential adjustments due to recapitalization events.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $3.7 million figure is an estimate.
- Confirm whether the underwriters exercised the 15% over-allotment option.
- Review the attached Underwriting Agreement (Exhibit 1.1) and Form of Warrant (Exhibit 4.1) for specific covenants and adjustment mechanisms.
- Check subsequent filings for the actual use of proceeds and any dilution impact on existing shareholders.